Chemotherapy News and Research

Latest Chemotherapy News and Research

Genta announces Phase 3 trial results of Genasense

Genta Incorporated today announced preliminary results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine (DTIC) administered with or without Genasense® in patients who have not previously received chemotherapy.

16 Nov 2009

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2009.

16 Nov 2009

Ginger effective in treating post-chemo nausea in cancer patients

Reed's, Inc., maker of the top-selling sodas in natural food stores nationwide, announced today that it will be exhibiting at the Chemotherapy Foundation Symposium XXVII New Perspectives in Oncology Practice Seminar, Saturday November 14th, at the Marriott Marquis in New York, NY.

16 Nov 2009

FDA provides marketing clearance for the Platelet PGD Test System

The U.S. Food and Drug Administration today cleared for marketing the Platelet PGD Test System, the first rapid test for the detection of bacterial contamination in pooled platelets derived from whole blood.

16 Nov 2009

Pro-Pharmaceuticals announces financial results for the third quarter and first nine months of fiscal 2009

Pro-Pharmaceuticals, Inc., a developer of galectin-targeted, carbohydrate therapeutic compounds to treat cancer and fibrosis, today reported its financial results for the third quarter and first nine months of fiscal 2009. These results are included in the Company’s Quarterly Report on Form 10-Q for the three- and nine-month periods ended September 30, 2009, which has been filed with the SEC.

13 Nov 2009

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Pharmacyclics, Inc. today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA.

13 Nov 2009

Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717

Axelar AB today announced that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor, will be presented next week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA.

13 Nov 2009

Breast cancer patients who undergo fertility preservation need not delay treatment

A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion.

13 Nov 2009

Innomed/BioRobotics to be Health Robotics' exclusive strategic partner in Korea

Health Robotics today announced that Innomed/BioRobotics, on the heels of its prior market success with Oncology Surgery robots, has exclusively selected Health Robotics' CytoCare(TM) Robot to reach its objective to become the gold standard for Oncology Robotics IV Admixtures in the Republic of Korea and synergistically provide an end-to-end Cancer Robotics solution.

13 Nov 2009

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented its results on new oral chemotherapy nanoparticle formulation at the AAPS (American Association of Pharmaceutical Scientists) Annual Meeting in Los Angeles (November 8 to 12, 2009).

13 Nov 2009

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology, today reported financial results for the third quarter ended September 30, 2009.

12 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

OPKO Health acquires NK-1 compounds from Schering

OPKO Health, Inc. today announced that it has completed the acquisition of rolapitant and a related compound from Schering Corporation, a subsidiary of Merck & Co., Inc. ("Schering").

11 Nov 2009

Bend Memorial Clinic to begin Phase III lung cancer trial

The Bend Memorial Clinic is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease’s recurrence in previously treated patients. Specifically, the trial is evaluating the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).

11 Nov 2009

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

OncoVista Innovative Therapies, Inc. reported today that two of its proprietary products, the AdnaTest™ BreastCancer and AdnaTest EMT1/StemCell, were evaluated in Germany by the Departments of Gynecology and Obstetrics and Internal Medicine (Cancer Research) at University Hospital Essen, University of Duisburg-Essen and the Department of Gynecology and Obstetrics, University Hospital of Tuebingen.

11 Nov 2009

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.

11 Nov 2009

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Poniard Pharmaceuticals, Inc. today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial.

11 Nov 2009

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures.

11 Nov 2009

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

11 Nov 2009

NIDA supports new drug detection research

Every time a person snorts cocaine, it doesn't just go to his or her head: It also provokes a response in the immune system, creating special biomolecules that may serve as a permanent record of each exposure.

11 Nov 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

Genta announces Phase 3 trial results of Genasense

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

Ginger effective in treating post-chemo nausea in cancer patients

FDA provides marketing clearance for the Platelet PGD Test System

Pro-Pharmaceuticals announces financial results for the third quarter and first nine months of fiscal 2009

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

Axelar AB to present data from ongoing Phase I/II clinical trial of AXL1717

Breast cancer patients who undergo fertility preservation need not delay treatment

Innomed/BioRobotics to be Health Robotics' exclusive strategic partner in Korea

Data on BioAlliance Pharma's oral chemotherapy nanoparticle formulation presented at the AAPS meeting

Spectrum Pharmaceuticals reports consolidated revenues of $7.1M for the third quarter of 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

OPKO Health acquires NK-1 compounds from Schering

Bend Memorial Clinic to begin Phase III lung cancer trial

OncoVista Innovative Therapies' AdnaTest BreastCancer and EMT1/StemCell products evaluated in German hospitals

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NIDA supports new drug detection research

Cancer Research - Second Edition eBook

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in